The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

Completed

Conditions studied: Non-small Cell Lung Cancer (NSCLC)

In brief

The primary objective of this study is to determine whether circulating tumor cells (CTCs) can be used as a non-invasive means of confirming pathologic diagnosis in early-stage (Stage I) non-small cell lung cancer (NSCLC). Patients scheduled to undergo surgical intervention will have blood samples obtained to test for CTCs. Presence of CTCs will be compared to final pathologic diagnosis based on surgical specimens to assess the sensitivity of using CTCs alone to make a definitive diagnosis.

Key facts

Study ID

NCT02380196

Run by

Abramson Cancer Center at Penn Medicine

People needed

100

Starts

2015-03-01

Expected to finish

2019-12-31

Last updated by the study team

2020-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of stage I NSCLC a. Only patients with a pathologically confirmed NSCLC will be retained for data analysis b. Should pathologic diagnosis reveal a more advanced stage, these subjects will remain in the study
• 18 years of age
• Ability to read and sign informed consent
• Both men and women and members of all races and ethnic groups are eligible for this trial.

You may not qualify if…

• Prior cancer diagnosis, excluding previously treated non-melanoma skin cancer
• Prior or ongoing treatment of the clinically diagnosed cancer

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.